Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ISIS 325568 administered to healthy volunteers

Next Previous
Trial Profile

A phase I, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ISIS 325568 administered to healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISIS 325568 (Primary) ; ISIS 325568 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals

Most Recent Events

  • 29 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA-2010), according to a Isis Pharmaceuticals media release.
  • 18 Aug 2008 Planned end date changed from 1 Jul 2008 to 1 Jun 2008, according to Clinicaltrials.gov.
  • 18 Aug 2008 Status changed from active, no longer recruiting to completed, reported by Clinicaltrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top